Chemotherapeutic agents and the skin: An update - 24/04/13
Abstract |
Chemotherapeutic agents give rise to numerous well described adverse effects that may affect the skin, hair, mucous membranes, or nails. The mucocutaneous effects of longstanding agents have been extensively studied and reviewed. Over the last 2 decades, a number of new molecular entities for the treatment of cancer have been approved by the United States Food and Drug Administration (FDA). This article reviews the cutaneous toxicity patterns of these agents. It also reviews one drug that has not received FDA approval but is in use outside the United States and is important dermatologically. Particular emphasis is placed on the novel signal transduction inhibitors as well as on newer literature pertaining to previously described reactions.
Learning objectives |
At the completion of this learning activity, participants should able to list the newer chemotherapeutic agents that possess significant mucocutaneous side effects and describe the range of reactions that are seen with each drug. In addition, they should be able to formulate appropriate management strategies for these reactions.
Le texte complet de cet article est disponible en PDF.Abbreviations used : 5-FU, AGEP, ATP, CLL, CML, EGFR, FDA, FIP1L1-PDGFR⍺, GIST, NSCLC, PDGFR⍺, PLD, PNP, SCC, VEGFR
Plan
Funding sources: None. |
|
Disclosure: Dr Burgin has received an educational grant from Johnson & Johnson. Drs Heidary and Naik have no conflicts of interest to declare. |
Vol 58 - N° 4
P. 545-570 - avril 2008 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?